AstraZeneca Stock Performance – 21 March 2026
Trading Overview
- Closing time: 05:53 PM Central Europe on Wednesday 21 March 2026.
- Price movement: Up 1.76 % during the 24‑hour period.
- Current price: GB £12,612.20 per share on major exchanges.
- Shares outstanding: 15.5 million.
- Market capitalization: GB £258.1 billion.
- Volume: GB £52.2 billion worth of shares traded in the last 24 hours.
- Month‑end change: Up 0.46 % since the end of the previous month.
- 200‑day simple moving average: GB £13,469.54.
- 52‑week range:
- High: GB £15,732.00 on 18 February 2026.
- Low: GB £9,892.00 on 15 July 2026.
Strategic Highlights
AstraZeneca is pursuing a long‑term growth strategy that prioritises large investments in new cancer therapies. The company is allocating billions of pounds to research and development, expanding research partnerships, and integrating artificial intelligence into clinical trials. Recent disclosures indicate a continued focus on oncology, particularly solid tumours, while balancing the need for rapid commercialisation against the typical longer development timelines in the pharmaceutical industry.
Related Stock Activity – 24 Hours Prior
| Ticker | Price Change | Current Price | Market Cap | P/E Ratio | Additional Notes |
|---|---|---|---|---|---|
| Nomad Foods (NOMD) | +2.48 % | USD 11.89 | USD 1.6 bn | 12.02 | – |
| Capri (CPRI) | +2.23 % | USD 16.13 | USD 1.8 bn | 20.93 | – |
| Brightstar Lottery (BRSL) | –0.74 % | USD 9.31 | USD 1.7 bn | 9.48 | Share repurchase program continued; treasury holdings increased; extension of contract with New York State Gaming Commission for an additional two years. |
| Genius Sports (GENI) | +1.67 % | USD 6.50 | USD 1.8 bn | – | – |
| Stolt‑Nielsen (SN6.F) | –0.60 % | EUR 32.90 | EUR 2.2 bn | 8.34 | – |
Company Profile – AstraZeneca PLC
- Headquarters: Cambridge, United Kingdom.
- Sector: Healthcare – pharmaceuticals and medical products.
- Business model: Conducts research, manufacturing, and sales across eight therapeutic areas: gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.
- Listing: London Stock Exchange.
- IPO: 12 May 1993.
- Website: www.astrazeneca.com
All information presented is sourced from publicly available market data and company disclosures as of the specified trading period.
